- Conditions
- COVID-19
- Interventions
- Ad26.COV2.S, BNT162b2, mRNA-1273, mRNA-1273.211, mRNA-1273.222, SARS-CoV-2 rS/M1
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 867 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 10
- States / cities
- Decatur, Georgia • Baltimore, Maryland • New York, New York + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–18
of 18
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Hyperglycemia, Vaccine Adverse Reaction
- Interventions
- None (not interventional)
- Other
- Lead sponsor
- Levenson, David I., M.D.
- Individual
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Boca Raton, Florida
- Conditions
- Breast Cancer Related Lymphedema, Covid19
- Interventions
- Survey
- Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 714 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Covid19
- Interventions
- COVID-19 vaccine
- Biological
- Lead sponsor
- Corewell Health East
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11,834 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Royal Oak, Michigan
- Conditions
- Systemic Allergic Reaction
- Interventions
- Pfizer-BioNTech COVID-19 Vaccine (Comirnaty), Placebo, Pfizer-BioNTech COVID-19 Vaccine, Bivalent
- Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 16 Years to 69 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Adverse Reaction to Vaccine, COVID19 Vaccine
- Interventions
- BNT162b2, mRNA-1273, AZD1222, CoronaVac, Sinopharm, Gam-COVID-Vac, JNJ-78436735, CVnCoV, NVX-CoV2373, BBV152
- Biological
- Lead sponsor
- Masaryk University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- COVID-19, Pregnancy; Infection
- Interventions
- mRNA COVID-19 vaccine (Pfizer or Moderna)
- Biological
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 14 Years to 55 Years · Female only
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2028
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- COVID-19
- Interventions
- Not listed
- Lead sponsor
- ClinOne, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 790 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Greenwood Village, Colorado
- Conditions
- Kidney Transplant Recipients
- Interventions
- BNT162b2 vaccine (Pfizer/BioNTech), mRNA-1273 vaccine (Moderna)
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Cancer
- Interventions
- COVID-19 Vaccination
- Biological
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,206 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Carmel, Indiana • Indianapolis, Indiana
- Conditions
- COVID-19, Corona Virus Infection
- Interventions
- Pfizer-BioNTech mRNA COVID-19 vaccine, Moderna mRNA COVID-19 vaccine
- Biological
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 137 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Relapsing Multiple Sclerosis (RMS)
- Interventions
- Ofatumumab, mRNA COVID-19 vaccine, interferon or glatiramer acetate
- Drug · Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Hollywood, Florida • Wellesley, Massachusetts + 4 more
- Conditions
- Covid19
- Interventions
- CVXGA1 low dose, CVXGA1 high dose
- Biological
- Lead sponsor
- CyanVac LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 4
- States / cities
- Bardstown, Kentucky • Rochester, New York • Cincinnati, Ohio + 1 more
- Conditions
- SARS CoV 2 Infection, COVID-19
- Interventions
- Pfizer/BioNTech (BNT162b2), Moderna
- Biological
- Lead sponsor
- DHR Health Institute for Research and Development
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 4
- States / cities
- Brownsville, Texas • Edinburg, Texas • Rio Grande City, Texas
- Conditions
- X-linked Agammaglobulinemia, XLA, Primary Immune Deficiency, CVID, Common Variable Immunodeficiency, Primary Antibody Deficiencies, Secondary Hypogammaglobulinemia
- Interventions
- Not listed
- Lead sponsor
- Duke University
- Other
- Eligibility
- 6 Months and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 3
- States / cities
- St. Petersburg, Florida • Chapel Hill, North Carolina • Durham, North Carolina
- Conditions
- COVID-19 Pneumonia, COVID-19
- Interventions
- Pfizer COVID-19 mRNA vaccine, Moderna COVID-19 mRNA vaccine
- Biological
- Lead sponsor
- Methodist Health System
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 100 participants
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Kidney Transplant Recipients, Liver Transplant Recipients
- Interventions
- Pfizer-BioNTech COVID-19 Vaccine 2023-2024, Moderna COVID-19 Vaccine 2023-2024, SOC IS Regimen, SOC IS Reduction
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 15
- States / cities
- San Diego, California • San Francisco, California • Atlanta, Georgia + 10 more
- Conditions
- Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
- Interventions
- Moderna mRNA-1273, BNT162b2, Ad26.COV2.S, Continue IS (MMF or MPA), Continue IS (MTX), Continue IS (B cell depletion therapy), Monovalent [B.1.351] CoV2 preS dTM-AS03, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, BNT162b2, Bivalent
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 29
- States / cities
- Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 18 more